rawpixel-shutterstock-com-5

Rawpixel / Shutterstock.com

29 October 2015Americas

Pfizer and Allergan merger talks at early stage

Pharmaceutical company Pfizer has confirmed it has entered into talks with generics company Allergan over a potential merger.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

More on this story

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

More on this story

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

AstraZeneca ‘has value’ says former Pfizer lawyer

28 April 2014 AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.

More features

UK firm expands in Germany with more litigation hires

Sandoz blocked by UK court from seeking Xarelto profits

An update on patenting in Ukraine, Russia and Eurasia

The rise of pro-NPE and patent sentiment in the US

UPC sees rising small molecule litigation with Pfizer in the hot seat

Why the Caribbean cannabis economy is ripe for IP protection

China filings push rise in patent applications in Ireland

Brain disorder medtech rivals butt heads at ITC